Puma Biotechnology
PBYI
88 hedge funds and large institutions have $115M invested in Puma Biotechnology in 2022 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 22 increasing their positions, 26 reducing their positions, and 15 closing their positions.
308% more call options, than puts
Call options by funds: $870K | Put options by funds: $213K
40% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 15
6% more funds holding
Funds holding: 83 → 88 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.96% less ownership
Funds ownership: 60.7% → 59.74% (-0.96%)
8% less capital inflows, than outflows
Capital inflows: $8.65M | Capital outflows: $9.44M
15% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$2.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$1.11M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
+$941K |
| 4 |
Two Sigma Investments
New York
|
+$691K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$398K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$2.42M |
| 2 |
D.E. Shaw & Co
New York
|
-$1.4M |
| 3 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$1.26M |
| 4 |
BlackRock
New York
|
-$1.13M |
| 5 |
Millennium Management
New York
|
-$399K |
PBYI Hedge Fund Activity: Q4 2022 in Review
88 of the 6,241 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q4 2022, worth a combined $115M — up 76% from $65.5M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new PBYI positions and 15 closed out — a net gain of 6 holders — while 22 added to existing stakes and 26 trimmed.
The largest buyer was Hillsdale Investment Management, opening a new position worth an estimated $2.3M. The largest seller was Armistice Capital, cutting an estimated $2.42M.
- 88 institutional investors held Puma Biotechnology (PBYI) as of Q4 2022, up from 83 in Q3 2022.
- Funds reported $115M of Puma Biotechnology stock for Q4 2022, up 76% quarter-over-quarter.
- 21 funds opened new Puma Biotechnology positions in Q4 2022 and 15 closed out, a net change of +6 holders.
- The largest Puma Biotechnology buyer in Q4 2022 was Hillsdale Investment Management, an estimated $2.3M added.
- The largest Puma Biotechnology seller in Q4 2022 was Armistice Capital, an estimated $2.42M sold.
Based on aggregated 13F filings for Q4 2022.